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Association of longitudinal risk 
profile trajectory clusters with 
adipose tissue depots measured by 
magnetic resonance imaging
Susanne Rospleszcz1,11*, Roberto Lorbeer2,9,11, Corinna Storz3, Christopher L. Schlett4, 
Christa Meisinger1,5, Barbara Thorand1, Wolfgang Rathmann6,7, Fabian Bamberg2,4, 
Wolfgang Lieb8,11 & Annette Peters1,9,10,11
The objective of the study was to identify associations of longitudinal trajectories of traditional 
cardiometabolic risk factors with abdominal and ectopic adipose tissue depots measured by magnetic 
resonance imaging (MRI). We measured total abdominal, visceral, and subcutaneous adipose tissue in 
liter and intrahepatic, intrapancreatic and renal sinus fat as fat fractions by MRI in 325 individuals free 
of cardiovascular disease at Exam 3 of a population-based cohort. We related these MRI measurements 
at Exam 3 to longitudinal risk profile trajectory clusters, based on risk factor measurements from 
Exam 3, Exam 2 (seven years prior to MRI) and Exam 1 (14 years prior to MRI). Based on the levels 
and longitudinal trajectories of several risk factors (blood pressure, lipid profile, anthropometric 
measurements, HbA1c), we identified three different trajectory clusters. These clusters displayed 
a graded association with all adipose tissue traits after adjustment for potential confounders (e.g. 
visceral adipose tissue: βClusterII = 1.30 l, 95%-CI:[0.84 l;1.75 l], βClusterIII = 3.32 l[2.74 l;3.90 l]; intrahepatic: 
EstimateClusterII = 1.54[1.27,1.86], EstimateClusterIII = 2.48[1.93,3.16]. Associations remained statistically 
significant after additional adjustment for the risk factor levels at Exam 1 or Exam 3, respectively. 
Trajectory clusters provided additional information in explaining variation in the different fat 
compartments beyond risk factor profiles obtained at individual exams. In conclusion, sustained high 
risk factor levels and unfavorable trajectories are associated with high levels of adipose tissue; however, 
the association with cardiometabolic risk factors varies substantially between different ectopic 
adipose tissues. Trajectory clusters, covering longitudinal risk profiles, provide additional information 
beyond single-point risk profiles. This emphasizes the need to incorporate longitudinal information in 
cardiometabolic risk estimation.
Obesity is an established risk factor for several disease conditions, including cardiovascular disease (CVD) 
and type 2 diabetes1,2, and clusters with other traditional CVD risk factors, such as hypertension and 
hypercholesterolemia3.
Easily applicable metrices such as body mass index (BMI) and waist circumference (WC) are often used as 
measures of obesity. However, both BMI and WC do not sufficiently reflect the distribution of fat in the body, nor 
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can they adequately quantify the amount of metabolically active adipose tissue4. For an appropriate quantifica-
tion of the amount and distribution of adipose tissue, non-invasive imaging is increasingly being used, including 
magnetic resonance imaging (MRI)5,6.
In addition to subcutaneous adipose tissue (SAT), also visceral adipose tissue (VAT) and ectopic fat depots, i.e. 
the accumulation of adipose tissue in and around organs, might have local as well as systemic metabolic effects 
and, thereby, modulate overall cardiometabolic risk7–9.
Prior studies have indeed shown that accurate quantification of adipose tissue, including VAT and SAT, pro-
vides additional value in the prediction of cardiometabolic outcomes (e.g. incident CVD, type 2 diabetes), beyond 
anthropometric measures10–13.
The relation of other ectopic fat depots with traditional markers of cardiometabolic risk is less established, but 
supported by more recent evidence. Hepatic fat has been reported to be cross-sectionally associated with hyper-
tension14, dyslipidemia15 and impaired glucose homeostasis16. Pancreatic fat showed associations with general 
obesity and diabetes17–19. For renal sinus fat, associations with hypertension and increased triglycerides have been 
reported20–22.
However, these associations of ectopic fat depots with cardiometabolic risk factors were only obtained in 
cross-sectional analyses and with varying imaging methodologies. It is not well known how the longitudinal 
exposure to multiple CVD risk factors relates to established MRI-derived fat compartments such as VAT and SAT, 
or to ectopic adipose tissue depots such as renal sinus fat. Therefore, in the present manuscript, we aimed to ana-
lyze the association of traditional CVD risk factor trajectories over a 14-year time horizon with different measures 
of adipose tissue, as determined by MRI. These fat measures include total adipose tissue (TAT), VAT, SAT, but also 
rather novel markers of ectopic fat, including renal sinus fat fraction (RSFF), intrahepatic fat fraction (HFF) and 
intrapancreatic fat fraction (PFF).
The trajectories of multiple cardiometabolic risk factors over time can be used to identify distinct longitudinal 
patterns, i.e clusters, reflecting different cumulative cardiometabolic risk factor exposure.
In our analyses, we aim to identify distinct longitudinal risk profile trajectory clusters, quantify the association 
of these clusters with adipose tissue traits and to determine their incremental value compared to single-point 
measurements of individual risk factors.
Methods
Study sample. We used longitudinal data from the KORA (Cooperative Health Research in the Region of 
Augsburg) S4 sample, a population-based cohort from Bavaria, Germany. The cohort has been examined repeat-
edly at three different time points (Exam 1, Exam 2, Exam 3). The sampling scheme and the examination proto-
cols of the KORA cohorts have been previously described in detail23,24. The baseline examination, Exam 1, was 
conducted in 1999–2001 and comprised 4261 participants; Exam 2 took place in 2006–2008 with 3080 partici-
pants; and Exam 3 was conducted in 2013–2014, including 2279 participants. At Exam 3, a whole-body MRI was 
obtained in a subsample of 400 participants free of CVD5. This MRI sub-sample included a high proportion of 
participants with prediabetes (26%) and diabetes (14%), because a specific aim of the KORA-MRI substudy was 
to evaluate subclinical CVD burden in individuals with prediabetes and diabetes5.
All study participants provided written informed consent. The study was approved by the ethics committee 
of the Bavarian Chamber of Physicians and the ethics committee of the Ludwig-Maximilians-University Munich 
and complies with the Declaration of Helsinki.
For the present analyses, a total of 75 of the 400 KORA-MRI study participants had to be excluded, because 
they did not participate in Exam 2 (n = 20) or because of missing values in any of the MRI parameters of interest 
(n = 55). Missing values in the MRI parameters were due to insufficient image quality, imaging artifacts and tech-
nical errors and were unrelated to the participants’ clinical covariates.
Covariate assessment. At all three examinations, participants underwent a comprehensive physical exam-
ination, a blood draw and a standardized face-to-face interview conducted by trained examiners.
Height and weight were determined by Seca’s measuring systems (Seca GmbH & Co, KG, Hamburg, Germany) 
with either calibrated steelyards or digital scales. Height was quantified to the closest 0.1 cm and weight to the 
closest 0.1 kg. BMI was calculated as weight in kg divided by squared height in m.
WC was measured with an inelastic tape at the level midway between the lower rib margin and the iliac crest. 
Hip circumference was measured at the level of maximal gluteal protrusion.
Blood pressure was measured on the right upper arm using an OMRON type HEM-705CP oscillometric 
device. After at least 5 minutes of rest, three measurements were taken at intervals of three minutes. The mean of 
the second and third blood pressure measurement was used for the present analyses. Hypertension was defined 
as systolic/diastolic blood pressure above 140/90 mmHg or intake of antihypertensive medication, given that the 
participant was aware of being hypertensive. Antihypertensive medication was defined according to German 
national guidelines25.
Laboratory measurements have been described previously26. Briefly, for the assessment of total cholesterol, 
LDL cholesterol and HDL cholesterol, enzymatic, photometric assays were used at Exam 1, and enzymatic, colori-
metric Flex assays were used at Exam 2 and Exam 3. HbA1c was measured by a turbidimetric inhibition immuno-
assay at Exam 1 and by cation-exchange high performance liquid chromatographic, photometric assays at Exam 
2 and Exam 3. Supplementary Table S1 provides a more detailed description of the laboratory measurements.
Diabetes status, cigarette consumption, physical activity, alcohol intake and medication intake were 
self-reported. Participants were labeled as being physically active if they reported engaging in sports activities 
regularly for ≥1 hour per week or as physically inactive if they reported engaging in sports activities irregularly 
and less than 1 hour per week. At Exam 3, glycemic status was additionally validated by an oral glucose tolerance 
test and categorized into normoglycemic, prediabetes or diabetes according to the WHO guidelines27.
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For our analysis, we used the following traits as traditional CVD risk factors: systolic blood pressure, diastolic 
blood pressure, BMI, WC, total cholesterol, HDL, LDL and HbA1c.
MRI outcome assessment. The whole-body MRI protocol of the KORA-MRI substudy has been previously 
described in detail5. In brief, all MRI scans were performed on a 3 Tesla Magnetom Skyra (Siemens Healthineers, 
Erlangen, Germany) using a table-mounted spine matrix coil together with an 18-channel whole-body radiofre-
quency coil. The whole-body MRI protocol comprised multiple sequences to cover head, cardiovascular system 
and abdominal region. All images were read by independent radiologists blinded to the participants’ clinical 
covariates and standard quality measures of inter-and intrareader variability were evaluated.
For quantification of adipose tissue compartments, volume-interpolated 3D in/opposed-phase VIBE-Dixon 
sequence was performed and adipose tissues were segmented semi-automatically28,29. SAT was quantified from cardiac 
apex to femoral head and VAT was quantified from diaphragm to femoral head; Total adipose tissue was defined as the 
sum of SAT and VAT, all indicated in liter. Figure 1 exemplifies the segmentation and quantification of VAT and SAT.
For the determination of HFF in %, a multi-echo Dixon-VIBE T1-weighted sequence was used, accounting for 
confounding T2* decay and spectral complexity of fat14. HFF was calculated as the mean fat fraction of right liver 
lobe (measured in segment VIII according to Couinaud classification) and left liver lobe (measured in segment 
II). An exemplary MRI image of HFF quantification is shown in Fig. 2A.
PFF was measured by the 3D multi-echo Dixon-VIBE sequence by drawing regions of interest into the pan-
creatic head, body and tail, and was measured as proton-density fat fraction in %30. An exemplary MRI image of 
PFF quantification is shown in Fig. 2B.
Additionally, based on the volume-interpolated 3D in/opposed-phase T1 weighted VIBE-Dixon sequence, 
an inhouse MATLAB algorithm was used for semi-automatic segmentation of total renal volume, renal cortex, 
medulla and sinus31. RSFF was then determined by overlaying the segmentation with the respective Water-Only 
and Fat-Only Dixon images. An exemplary MRI image is shown in Fig. 2C.
Statistical analysis. Descriptive statistics. Continuous variables are summarized by arithmetic means and 
standard deviation (SD) and categorical variables are presented as counts and percentages. Differences in varia-
bles between Exam 1, Exam 2 and Exam 3 were evaluated by repeated measures ANOVA and Cochran’s Q-Test, 
respectively. MRI-derived adipose tissue outcome variables at Exam 3 are summarized as mean and SD or median 
with interquartile range.
We created models based on single-point risk profiles and models based on longitudinal trajectory clusters to 
be able to determine the additional value of longitudinal trajectories.
Association of single-point risk profiles at individual Exams with adipose tissue. To assess the association of 
single-point risk profiles at Exam 1, Exam 2 and Exam 3 (each Exam considered separately) with the different 
adipose tissue variables as outcomes, linear regression models were constructed. Due to their skewed distribution, 
Figure 1. MRI-based assessment of visceral (VAT; red) and subcutaneous (SAT; yellow) adipose tissue in a 
46-year-old male (VAT 6.57 l), displayed in coronar (A), sagittal (B) and axial (C) slices.
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HFF and PFF were log-transformed prior to analysis. The risk profile included eight variables: systolic blood pres-
sure, diastolic blood pressure, BMI, WC, total cholesterol, HDL, LDL and HbA1c. The outcome variables com-
prised TAT, SAT, VAT, RSFF, log (HFF) and log (PFF). As adjustment covariates, the models included age, sex, 
antihypertensive medication, lipid-lowering medication, smoking behavior and diabetes. All continuous variables 
were standardized (mean = 0, sd = 1) prior to analysis. The Goodness-Of-Fit statistic R2 served as a measure of 
how much variance in the outcome is explained by the respective statistical model.
Identification of longitudinal risk factor clusters. We then identified longitudinal trajectories of risk factor pro-
files, using information from Exam 1, Exam 2 and Exam 3 simultaneously. Longitudinal risk factor trajectories 
were computed by unsupervised non-parametric k-means clustering using Euclidean distance32. Briefly, partic-
ipants within one cluster should be similar to each other with regard to their risk profile, and dissimilar from 
participants in other clusters. We used Euclidean distance to determine the closeness of risk factor values between 
individuals and a mathematical norm function to determine the similarity of the resulting risk factor vectors33. 
Importantly, this automated clustering algorithm is unbiased and does not depend on pre-determined risk factor 
value cut-offs. Based on visual inspection and Calinski-Harabasz criterion, the optimal number of clusters was 
three. According to their individual multivariate trajectories, each study participant was automatically assigned to 
one of the three clusters, denoted by Roman Numericals as Cluster I, Cluster II and Cluster III.
Association of longitudinal risk profile trajectories with adipose tissue. Subsequently, associations of the trajectory 
clusters with adipose tissue outcomes were evaluated by linear regression models adjusted for age, sex, antihy-
pertensive medication, lipid-lowering medication, smoking status and diabetes, all of them measured Exam 3. 
The trajectory clusters entered the linear model as a categorical variable with three levels. Cluster I served as the 
reference category and estimates were obtained for Cluster II and Cluster III. Furthermore, in order to assess 
whether longitudinal trajectory clusters provided additional information beyond the risk factor values obtained 
at the beginning (Exam 1) or end of the study (Exam 3), we created two additional models: The above model was 
additionally adjusted for the risk profile of Exam 1 or additionally adjusted for the risk profile at Exam 3, respec-
tively. For all models, R2 was calculated as a measure of variance explained.
Additionally, as sensitivity analyses, all analyses were repeated with BMI and WC excluded from the risk pro-
file variables and instead used as outcomes variables.
Two sided p-values < 0.05 were considered to indicate statistical significance. All computations were performed 
with Stata 14.1 (Stata Corporation, College Station, Texas, USA) and R 3.4.1 (R Core Team, Vienna, Austria).
Figure 2. Exemplary MRI images of ectopic fat quantification. (A) Quantification of hepatic fat fraction. 
The dual-echo Dixon sequence shows the region of interest (orange square) placed in the liver parenchyma 
on the level of the portal vein. Results of the multi-echo spectroscopy are displayed as graph and colored bar. 
(B) Quantification of pancreatic fat fraction. Using a multi-echo Dixon-VIBE sequence, circular regions of 
interest were drawn into the pancreatic caput (B1), corpus (B2) cauda (B3) and resulting proton-density fat 
fractions were averaged. (C) Quantification of renal sinus fat fraction. Displayed is the overlay of renal sinus 
segmentation with Water-Only (C1) and Fat-Only (C2) Dixon images.
5Scientific RepoRtS |         (2019) 9:16972  | https://doi.org/10.1038/s41598-019-53546-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
Results
Trends in risk factor profiles. The cardiometabolic risk factor profiles at Exam 1, Exam 2 and Exam 3 are 
presented in Table 1. The sample comprised 59.4% men; mean age at baseline was 42.2 years. Over the course of 
14 years, mean systolic and diastolic blood pressure declined significantly, while the percentage of individuals 
treated with antihypertensive medication increased significantly. Mean body weight, WC and BMI increased 
(Table 1). Mean HbA1c and prevalence of diabetes increased, whereas total cholesterol decreased. Alcohol con-
sumption remained stable and more participants quit smoking and became physically active. A description of the 
different MRI-derived adipose tissue traits that served as outcome variables is provided in Table 2.
Associations of single-point risk profiles with adipose tissue traits. Figure 3 shows the ability of individ-
ual single-point risk profiles at Exam 1, Exam 2 and Exam 3, respectively, to explain the variance in the different adipose 
tissue traits. At each Exam, the risk profile explained only a modest proportion of the variation in pancreatic and renal 
sinus fat and the amount of variation explained by the risk factors was similar across Exams 1 to 3 (about 20% to 30% 
of variance explained, Fig. 3). For hepatic fat (HFF), a moderate proportion of variance was explained by the individual 
risk profiles with a slight increase from Exam 1 (above 40%) to Exam 3 (above 50%). For TAT, SAT and VAT, the indi-
vidual risk profiles explained a large proportion of the variance in the adipose traits with a substantial increase from 
Exam 1 (around 60% of variance explained) to Exam 3 (almost 90% of variance explained for TAT).
In sensitivity analyses, when we excluded BMI and WC from the risk factor profiles, the amount of variance 
explained was considerably lower for all adipose tissue traits (compare Supplementary Figure S1). The highest R2 values 
were obtained for VAT, WC and HFF (all R2 > 0.4), whereas the values for SAT and BMI were substantially decreased.
Characterization of longitudinal risk profile trajectory clusters. By multivariate longitudinal 
k-means clustering, three distinct clusters of risk profile trajectories over a time period of 14 years were identi-
fied. In essence, the clusters differ in mean risk factor levels and in change over time of the individual risk factors 
Exam 1 Exam 2 Exam 3
p-value(1999–2001) (2006–2008) (2013–2014)
Men 193 (59.4%) 193 (59.4%) 193 (59.4%)
Age, years 42.2 ± 9.2 49.2 ± 9.2 56.2 ± 9.2
Systolic BP, mmHg 126.5 ± 16.4 121.3 ± 16.5 121.1 ± 16.4 <0.01
Diastolic BP, mmHg 81.6 ± 10.5 76.4 ± 9.6 75.6 ± 10.1 <0.01
Hypertension, # of individuals 94 (28.9%) 80 (24.6%) 109 (33.5%) <0.01
Antihypertensive Treatment, # of 
individuals 25 (7.7%) 43 (13.2%) 77 (23.7%) <0.01
BMI, kg/m2 26.6 ± 3.8 27.3 ± 4.2 28.0 ± 4.7 <0.01
Weight, kg 78.8 ± 13.3 81.4 ± 14.8 82.9 ± 16.0 <0.01
Waist Circumference, cm 90.4 ± 11.5 93.6 ± 12.9 98.3 ± 13.8 <0.01
Hip Circumference, cm 104.4 ± 6.8 106.0 ± 7.7 106.6 ± 8.5 <0.01
Waist-To-Hip-Ratio 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 <0.01
Total Cholesterol, mg/dL 223.8 ± 40.1 214.6 ± 36.7 218.4 ± 36.9 <0.01
LDL Cholesterol, mg/dL 134.0 ± 39.0 137.6 ± 32.8 140.4 ± 33.0 n.s
HDL Cholesterol, mg/dL 56.1 ± 17.2 53.6 ± 14.2 61.7 ± 18.1 <0.01
Ratio Total Cholesterol/HDL 4.4 ± 1.6 4.2 ± 1.2 3.8 ± 1.3 <0.01
Ratio LDL/HDL 2.7 ± 1.2 2.7 ± 1.0 2.5 ± 1.0 0.01
Lipid-lowering Medication, # of 
individuals 5 (1.5%) 20 (6.2%) 32 (9.8%) <0.01
Diabetes mellitus, self-reported, # 
of individuals 3 (0.9%) 14 (4.3%) 27 (8.3%) <0.01
HbA1c, % 5.5 ± 0.5 5.5 ± 0.5 5.6 ± 0.7 0.02
Antidiabetic Medication, # of 
individuals 3 (0.9%) 8 (2.5%) 24 (7.4%) <0.01
Alcohol consumption, g/day 19.5 ± 25.3 17.9 ± 23.5 18.3 ± 22.2 n.s
Smoking, # of individuals 0.04
  never-smoker 121 (37.2%) 121 (37.2%) 121 (37.2%)
  ex-smoker 116 (35.7%) 133 (40.9%) 140 (43.1%)
  smoker 88 (27.1%) 71 (21.8%) 64 (19.7%)
Physically active, # of individuals 161 (49.5%) 192 (59.1%) 198 (60.9%) <0.01
Table 1. Cardiometabolic risk profile of the study sample (N = 325) at Exam 1, Exam 2 and Exam 3 (time of 
MRI examination) Continuous variables are presented as mean and standard deviation with p-values calculated 
by repeated measures ANOVA, indicating whether the mean values differ significantly in at least two time 
points. Categorical variables are presented as counts and percentages with p-values calculated by Cochrans Q 
Test, indicating whether the percentage of subjects differ significantly in at least two time points.
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(Fig. 4 and Supplementary Table S2). Specifically, Cluster I comprises 114 individuals (35% of the overall sample) 
and represents the lowest cardiometabolic risk burden. It includes individuals with the youngest average age, and 
the lowest mean levels of systolic and diastolic blood pressure, WC, BMI, HbA1c, total and LDL cholesterol at 
baseline. In addition, Cluster I is characterized by the lowest increase of WC and BMI and the highest increase 
of lipid parameters over time. Cluster II comprises 129 individuals (40% of the overall sample). Mean age, mean 
blood pressure values, mean BMI and WC, HbA1c and HDL reside between Cluster I and Cluster III. However, 
total cholesterol and LDL values are higher in this cluster than in the other two clusters.
Cluster III, comprising 82 individuals (25% of the overall sample), has the highest mean age and highest lev-
els of blood pressure, BMI, and WC as well as the lowest levels of HDL at Exam 1. Furthermore, BMI, WC and 
HbA1c increased over time with the highest % change of all clusters (see Supplementary Table S2).
Association of longitudinal risk profile trajectory clusters to adipose tissue traits. Figure 5 
shows the distribution of the MRI-derived adipose tissue traits, measured at Exam 3, according to the three 
longitudinal trajectory clusters. Cluster I reflects low, Cluster II reflects moderate and Cluster III reflects high 
cumulative exposure to cardiometabolic risk factors over 14 years. A gradual increase in adipose tissue content 
for all traits is discernible from Cluster I to III, with the differences being statistically significant (all p < 0.001).
When we excluded BMI and WC from the risk factor set, the graded relation between the clusters with respect 
to the adiposity traits was less consistent (compare Supplementary Figure S2). Adipose tissue levels in Cluster I 
were lower compared to the other two clusters, but the average levels of different adipose tissue traits between 
Cluster II and III were comparable, e.g for TAT and SAT. Average BMI levels were similar between Cluster II and 
III (28.8 ± 4.2 kg/m2 and 29.4 ± 4.6 kg/m2, respectively), whereas WC levels were significantly lower in Cluster II 
compared to Cluster III (101.3 ± 11.4 cm vs 105.3 ± 13.1 cm, p = 0.02).
Upon multivariable adjustment for age, sex, antihypertensive and lipid-lowering medication, smoking and 
diabetes, the trajectory clusters were significantly associated with all adipose tissue outcomes (“fully adjusted” 
model in Table 3). For example, Cluster II was associated with an increase of 1.30 l in VAT (95%-CI 0.84 to 1.75) 
and a 2.60 l increase in SAT (95%-CI 1.87 to 3.34) whereas Cluster III was associated with an increase of 3.32 l 
N = 325
TAT, l 12.6 ± 5.3
VAT, l 4.5 ± 2.7
SAT, l 8.1 ± 3.6
RSFF, % 63.9 ± 9.9
HFF, % (median[IQR]) 5.7 [3.0, 11.7]
PFF, % (median[IQR]) 5.4 [3.4, 9.2]
Table 2. MRI-derived adipose tissue measures of the study sample (N = 325), obtained at Exam 3. TAT: Total 
adipose tissue, VAT: Visceral adipose tissue, SAT: Subcutaneous adipose tissue, RSFF: Renal sinus fat fraction, 
HFF: Hepatic fat fraction, PFF: Pancreatic fat fraction.
Figure 3. Goodness-of-Fit of the linear regression models estimating the association of single-point risk 
profiles with adipose tissue outcomes. On the x-axis: single time points at which risk profiles were obtained: 
Exam 1, Exam 2, Exam 3. On the y-axis: Goodness-of-Fit as measured by explained variance in outcome 
(adjusted R2). The single time points are connected by lines for visual aid only. The risk factor profiles included 
systolic blood pressure, diastolic blood pressure, BMI, WC, Total Cholesterol, HDL, LDL and HbA1c whereas 
the outcome variables comprised TAT, SAT, VAT, RSFF, log (HFF) and log (PFF).TAT: Total adipose tissue, 
VAT: Visceral adipose tissue, SAT: Subcutaneous adipose tissue, RSFF: Renal sinus fat fraction, HFF: Hepatic fat 
fraction, PFF: Pancreatic fat fraction
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Figure 4. Mean risk factor levels at Exam 1, Exam 2 and Exam 3 according to cluster membership of 
participants. Cluster membership in either Cluster I, Cluster II or Cluster III was determined by multivariate 
k-means clustering based on individual longitudinal risk profile trajectories.
Figure 5. Box plots illustrating the distribution of adipose tissue depots, measured at Exam 3, according 
to cluster membership of participants. Cluster membership in either Cluster I, Cluster II or Cluster III was 
determined by multivariate k-means clustering based on individual longitudinal risk profile trajectories. TAT: 
Total adipose tissue, VAT: Visceral adipose tissue, SAT: Subcutaneous adipose tissue, RSFF: Renal sinus fat 
fraction, HFF: Hepatic fat fraction, PFF: Pancreatic fat fraction.
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in VAT (95%-CI 2.74 to 3.90) and a 6.16 l increase in SAT (95%-CI 5.23 to 7.10); always compared to Cluster I 
(Referent). In the same vein, Cluster II was associated with a 52% increase in PFF (95%-CI 26 to 84) and Cluster 
III was associated with a 120% increase in PFF (95%-CI 73 to 180), compared to Cluster I.
When BMI and WC were excluded from the risk factor set, associations were attenuated and less graded, 
e.g. Cluster II was associated with an increase of 1.09 l in VAT (95%-CI:[0.53; 1.66]) and a 1.57 l increase in SAT 
(95%-CI:[0.62; 2.53]) whereas Cluster III was associated with an increase of 1.09 l in VAT (95%-CI:[0.48; 1.70]) 
and a 1.71 l increase in SAT (95%-CI:[0.68, 2.74]).
After adjustment for the risk profile obtained at Exam 1, the associations of the clusters with adipose tissue 
traits were attenuated but remained highly statistically significant (Table 3). The model including both the trajec-
tory cluster and the risk profile from Exam 1 explained more variation of the different fat compartments than the 
risk profile from Exam 1 alone (Supplementary Table S3). This indicates that the longitudinal information com-
prised in the clusters provides additional information, beyond the risk factor values measured at the beginning 
of the study (Exam 1).
After adjustment for the risk profile at Exam 3, trajectory clusters were still significantly associated with TAT, 
VAT and PFF (Table 3). Importantly, R2 measures for TAT, VAT, RSFF, HFF and PFF were higher compared to 
the model using solely the risk profile at Exam 3 (compare Supplementary Table S3). This indicates that the lon-
gitudinal information comprised in the clusters provides additional information, beyond the risk factor values 
measured concurrent to the MRI examination (Exam 3).
Discussion
We analyzed longitudinal trajectories of multiple cardiometabolic risk factors by identifying multivariate clusters, 
and evaluated the association of these longitudinal risk profile trajectory clusters with a broad panel of MRI-derived 
abdominal and ectopic adipose tissue traits. Our main findings are threefold: First, a high and sustained cumulative 
risk factor exposure is associated with larger amounts of adipose tissue. Second, the variability in adipose tissue that 
is explained by traditional CVD risk factors varies substantially, with rather modest values for localized ectopic tissue 
depots such as renal sinus fat and pancreatic fat and high values for systemic metabolic organs such as VAT and SAT. 
Third, longitudinal risk profile information provides additional value, beyond single-point analyses.
Identification of trajectory clusters. A clustering of CVD risk biomarkers is common34,35. However, 
data on the dynamic changes of several cardiometabolic risk factors over time are limited. We used an unbiased 
method, not depending on arbitrary cut-points, to classify individuals according to their longitudinal risk profile 
trajectories results by using a multivariate, unsupervised algorithm. We identified three clusters, which reflect low, 
medium and high cumulative risk factor exposure over 14 years. The identified trajectories are based on the mean 
risk factor values and the change in mean risk factor levels from Exam 1, Exam 2 and Exam 3.
outcome Model
Cluster I Cluster II Cluster III
estimate 95%-CI p-value estimate 95%-CI p-value
TAT
fully adjusted Ref. 3.90 [2.89, 4.91] <0.01 9.49 [8.20, 10.78] <0.01 R2 = 0.54
fully adjusted + risk profile Exam 1 Ref. 3.21 [2.14, 4.29] <0.01 6.25 [4.73, 7.77] <0.01 R2 = 0.65
fully adjusted+risk profile Exam 3 Ref. 0.39 [−0.26, 1.04] n.s 0.96 [0.09, 1.82] 0.03 R2 = 0.89
VAT
fully adjusted Ref. 1.30 [0.84, 1.75] <0.01 3.32 [2.74, 3.90] <0.01 R2 = 0.63
fully adjusted + risk profile Exam 1 Ref. 1.16 [0.63, 1.69] <0.01 2.62 [1.87, 3.37] <0.01 R2 = 0.66
fully adjusted + risk profile Exam 3 Ref. 0.17 [−0.30, 0.65] n.s 0.90 [0.26, 1.53] <0.01 R2 = 0.76
SAT
fully adjusted Ref. 2.60 [1.87, 3.34] <0.01 6.16 [5.23, 7.10] <0.01 R2 = 0.48
fully adjusted + risk profile Exam 1 Ref. 2.05 [1.30, 2.81] <0.01 3.63 [2.56, 4.70] <0.01 R2 = 0.63
fully adjusted + risk profile Exam 3 Ref. 0.22 [−0.26, 0.70] n.s 0.06 [−0.59, 0.71] n.s R2 = 0.87
RSFF
fully adjusted Ref. 3.39 [1.02, 5.76] <0.01 3.20 [0.18, 6.22] 0.04 R2 = 0.29
fully adjusted + risk profile Exam 1 Ref. 2.47 [−0.41, 5.35] n.s 0.31 [−3.77, 4.39] n.s R2 = 0.29
fully adjusted + risk profile Exam 3 Ref. 0.19 [−2.80, 3.18] n.s −2.28 [−6.28, 1.72] n.s R2 = 0.33
HFF
fully adjusted Ref. 1.54 [1.27, 1.86] <0.01 2.48 [1.93, 3.16] <0.01 R2 = 0.43
fully adjusted + risk profile Exam 1 Ref. 1.51 [1.21, 1.90] <0.01 2.23 [1.62, 3.03] <0.01 R2 = 0.47
fully adjusted + risk profile Exam 3 Ref. 1.14 [0.91, 1.43] n.s 1.32 [0.98, 1.79] n.s R2 = 0.53
PFF
fully adjusted Ref. 1.52 [1.26, 1.84] <0.01 2.20 [1.73, 2.80] <0.01 R2 = 0.24
fully adjusted + risk profile Exam 1 Ref. 1.52 [1.21, 1.92] <0.01 1.82 [1.32, 2.51] <0.01 R2 = 0.26
fully adjusted + risk profile Exam 3 Ref. 1.40 [1.10, 1.79] <0.01 1.58 [1.15, 2.20] <0.01 R2 = 0.27
Table 3. Association of longitudinal risk profile trajectory clusters with different adipose tissue traits and 
impact of additional adjustment for risk factors obtained at Exam 1 or Exam 3. Estimates are derived from a 
linear regression model. Cluster I served as reference category, i.e. estimates describe the change in adipose 
tissue outcome that is associated with membership in Cluster II (or Cluster III) as compared to membership 
in Cluster I. Estimates for TAT, VAT, SAT and RSFF are given as β-coefficients. Estimates for HFF and PFF are 
back-transformed from log-transformation and are therefore given as %change of the geometric mean. The fully 
adjusted model is adjusted for age, sex, antihypertensive medication, lipid-lowering medication, smoking status, 
and validated diabetes.
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Association of longitudinal risk factor trajectories with MRI adipose tissue traits. Traditional 
CVD risk factors explained substantial amounts of variability in SAT, VAT and hepatic fat (all R2 > 50%, Fig. 3). 
These adipose tissue depots are highly metabolically active organs36,37. For smaller, more localized fat depots 
(renal sinus fat, pancreatic fat), longitudinal clusters of traditional CVD risk factors were strongly statistically 
associated, but could explain only a smaller amount of variability. This indicates different biological mechanisms 
and pathways in the relation of traditional CVD risk factors to these fat compartments.
Total abdominal, visceral and subcutaneous fat. In our study, both VAT and SAT were strongly associated with 
traditional CVD risk profiles. These observations are in line with results from the Jackson Heart Study, where SAT 
and VAT were cross-sectionally associated with hypertension, fasting plasma glucose, triglycerides and HDL38,39 
and also with results from the Framingham Heart Study, where VAT and SAT were associated with hypertension, 
plasma glucose and lipid profile22,40,41. Our results corroborate that increased SAT is not associated with a more 
favorable cardiometabolic risk profile39,42. In our analysis, SAT had the highest R2 value of all adipose tissue 
depots, i.e. the highest amount of variation that could be explained by the risk profile. However, when BMI and 
WC were excluded from the risk profile, the R2 value for SAT became substantially smaller and was lower than 
that of VAT. The high value for SAT might therefore have been mainly driven by the high correlation of SAT with 
anthropometric measurements. This in line with other studies reporting an attenuated association of SAT to car-
diometabolic risk markers after adjustment for BMI or WC39,42,43.
VAT contributes to CVD risk e.g. by elevated lipolytic activity, increased low-grade inflammation, and raised 
production of cytokines and other chemical messenger compounds44. Unfavorable health effects of excess abdom-
inal adipose tissue are well established45. An important observation from our study is that longitudinal trajectory 
clusters were significantly associated with VAT, even in addition to the risk profile concurrent to the VAT quan-
tification. Thus, our results highlight the importance of taking an individual’s risk profile history into account to 
more accurately quantify the cardiometabolic risk associated with VAT.
Hepatic fat fraction. In our study, more than half of the variance in hepatic fat could be explained by traditional 
CVD risk factors. In line with our observations, unfavorable BMI trajectories over the life course (25 years) 
were associated with an increased risk of developing non-alcoholic fatty liver disease (NAFLD) in the CARDIA 
study46. A correlation of NAFLD with general obesity is now well established37. A recent Chinese study found 
cross-sectional associations of NAFLD with overall obesity, increased lipids, impaired glucose homeostasis and 
uric acid47. The Framingham Heart Study reports associations of fatty liver with unfavorable glycemic traits and 
unfavorable lipid profile15. Moreover, a modulation of hepatic fat by VAT has been proposed48,49.
Formation of hepatic fat is a complex, long-term process with a multifactorial etiology50. Elevated hepatic fat is 
related to CVD, in part by its contribution to insulin resistance, increased free fatty acids and chronic inflamma-
tion48,51. An important finding from our study is that longitudinal trajectory clusters provided additional explan-
atory value for hepatic fat, beyond the baseline measurements and also beyond the measurements concurrent to 
the fat quantification, although this additional contribution was minor. Hence, our results underline the impor-
tance of accounting for an individual’s longitudinal risk factor levels to improve estimation of cardiometabolic 
risk associated with hepatic fat.
Pancreatic fat fraction. In our study, longitudinal risk profile trajectory clusters explained only a quarter of the 
variance in pancreatic fat, which was the lowest value of all adipose tissue depots analyzed. The interrelation of 
pancreatic fat and cardiometabolic disease conditions is not entirely clear48,52. For example, studies on the associ-
ation of pancreatic fat with impaired glucose metabolism and type 2 diabetes are inconclusive30,53. Other studies 
have reported that pancreatic fat content is associated with serum triglyceride and nutritional fat intake54 and 
responsive to exercise and nutrition changes55. A recent meta-analysis of pancreatic steatosis found significant 
associations with metabolic syndrome, central obesity and hypertension, however with substantial heterogeneity 
between the studies56. Interestingly, although hepatic and pancreatic fat have been reported to be highly corre-
lated19,54, we observed differential associations of liver and pancreatic fat with a traditional CVD risk profile.
Importantly, our study showed that longitudinal trajectory clusters were significantly associated with pancre-
atic fat, even in addition to the risk profile concurrent to pancreatic fat quantification.
Our results therefore emphasize that longitudinal risk factor information should be taken into account while 
further elucidating the role of this localized ectopic fat depot in the metabolism of traditional CVD risk factors.
Renal sinus fat fraction. We observed in our sample that approximately a third of the variance in renal sinus 
fat could be explained by traditional CVD risk factors. Very few studies have reported associations of traditional 
CVD risk factors with renal sinus fat. A clinical study including 51 NAFLD patients reported no significant asso-
ciation of renal sinus fat fraction to BMI, cholesterol, HDL and fasting glucose57. Similarly, in 205 participants of 
the PREDICT study, an association of renal sinus fat with the number of antihypertensive medications taken was 
reported, but no significant association to BMI or diabetes was observed20. In the Framingham Heart Study, asso-
ciations of renal sinus fat as determined by Computed Tomography with hypertension, chronic kidney disease 
and increased triglyceride levels were reported21,22.
Adipose tissue in the renal sinus can lead to increased pressure on the renal vasculature and thereby to struc-
tural damage in the kidney58. Associations of renal sinus fat with blood pressure and renal function have been 
proposed21,59. However, the metabolic role of renal sinus fat has not been fully clarified. A recent clinical trial 
reported that ectopic fat depots were affected by overall weight loss, but renal sinus fat was not modified by spe-
cific interventions such as diet and physical activity59.
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In our analysis, longitudinal risk factor trajectories provided no distinct additional explanatory value for renal 
sinus fat. Our results therefore emphasize that the long-term effects and development of renal sinus fat have to be 
further elucidated to understand the role of this localized ectopic fat depot in the metabolism of traditional CVD 
risk factors.
Strengths and limitations. Limitations of our study include the relatively small sample size which did not 
allow subgroup analyses, e.g. sex-stratified analyses. Furthermore, we only included CVD risk factors that were 
available for all participants at all examination time points. We acknowledge that several other risk factors, such 
as triglycerides, glucose levels, inflammation markers or liver enzymes have been hypothesized to be associated 
with ectopic fat depots42,43,47. Besides, over the course of 14 years and three examination time points, laboratory 
methods, instruments and assays inevitably changed. This might have affected the values of our CVD risk factor 
measurements and thus the derived trajectories. For example, HDL values at Exam 3 are rather high, whereas 
values at Exam 2 are comparable to those of other German cohorts from the same time period60–62. Furthermore, 
MRI measurements were only available at Exam 3; therefore we could not assess the change in the different 
fat depots over time. It is likely that those individuals with unfavorable risk factor profiles also had the highest 
amounts of ectopic adipose tissue at baseline, but this cannot be examined given the available data. Analysis of 
longitudinal MRI measures of ectopic fat would provide higher-level evidence regarding the association with 
traditional CVD risk factors. However, longitudinal, whole-body MRI measurements from population-based 
cohort studies are still scarce63.
A major strength of our analyses is the longitudinal study design with repeated standardized assessment of sev-
eral established CVD risk factors over a long time period and the availability of a broad panel of MRI-determined 
adipose tissue measures. Furthermore, MRI is considered to be the gold standard for accurate quantification of 
adipose tissue. Another major strength of our study is the use of an automated clustering algorithm which charac-
terizes participants based on their cardiometabolic risk factor profiles, thus obtaining an unbiased classification.
Translational potential and conclusions. In conclusion, we report three main findings with translation 
potential. First, unfavorable risk factor trajectories, representing long cumulative exposure to elevated levels of 
cardiometabolic risk factors, are associated with increased adipose tissue depots. This underscores the need for 
rigorous management of traditional CVD risk factors. Second, CVD risk factors explained less variability in 
localized fat depots compared to highly systemically active fat depots. This implicates different pathophysiological 
pathways of these fat depots in CVD risk factor metabolism and cardiometabolic risk. Third, longitudinal risk fac-
tor trajectories add incremental information, above and beyond risk profiles obtained at individual time points, 
regarding their association with adipose tissue depots. This emphasizes the need to incorporate an individual’s 
longitudinal risk factor information to obtain improved estimation of the cardiometabolic risk that is associated 
with these adipose tissue depots.
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